<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/179"/><api:result><api:object category="publication" id="179" last-affected-when="2024-04-14T23:13:48.013+01:00" last-modified-when="2024-04-14T23:13:48.013+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/179" created-when="2010-05-17T13:46:12.77+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-04-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="94893" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033119771" last-modified-when="2024-04-10T11:51:15.477+01:00"><api:citation-count>368</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at I and 6 h after treatment and a very large decrease in tumor blood flow, which-by 6 h-was reduced approximately 100- fold. The spleen was the most affected normal tissue with a 7-fold reduction ill blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, NÏ‰- nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005831992</api:identifier></api:identifiers></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6602173965</api:identifier></api:identifiers></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">55725881600</api:identifier></api:identifiers></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005120741</api:identifier></api:identifiers></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7006468538</api:identifier></api:identifiers></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MRL</api:initials><api:first-names>MRL</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005615669</api:identifier></api:identifiers></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7202798776</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7103344024</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10197639</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Research</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record><api:record format="native" id="179" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10197639" last-modified-when="2020-04-29T03:26:01.237+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which-by 6 h-was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N(omega)-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MR</api:initials><api:first-names>MR</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10197639</api:text></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Res</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Blood Pressure</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Phosphorylation</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Regional Blood Flow</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword><api:keyword scheme="mesh">Vascular Resistance</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>United States</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>21</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record><api:record format="native" id="858442" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10197639" last-modified-when="2022-02-02T04:04:34.953+00:00"><api:citation-count>186</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which-by 6 h-was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N(omega)-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MR</api:initials><api:first-names>MR</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1538-7445</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10197639</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword><api:keyword scheme="mesh">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Phosphorylation</api:keyword><api:keyword scheme="mesh">Blood Pressure</api:keyword><api:keyword scheme="mesh">Vascular Resistance</api:keyword><api:keyword scheme="mesh">Regional Blood Flow</api:keyword><api:keyword scheme="mesh">Male</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>10</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record><api:record format="native" id="2470767" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1074356036" last-modified-when="2024-04-14T23:13:48.017+01:00"><api:citation-count>289</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0736063251.63</api:identifier></api:identifiers></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01331470172.55</api:identifier></api:identifiers></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01146336315.48</api:identifier></api:identifiers></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0642071130.28</api:identifier></api:identifiers></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.015101415237.16</api:identifier></api:identifiers></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MR</api:initials><api:first-names>MR</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0604150730.44</api:identifier></api:identifiers></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01261225425.23</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0745300522.28</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10197639</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Cardiovascular</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="hrcs-rac">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cardiovascular</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Blood Pressure</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Phosphorylation</api:keyword><api:keyword scheme="mesh">Rats</api:keyword><api:keyword scheme="mesh">Regional Blood Flow</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword><api:keyword scheme="mesh">Vascular Resistance</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>7.03</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record><api:record format="native" id="239929" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000079527800041" last-modified-when="2024-03-14T05:33:30.387+00:00"><api:citation-count>341</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">AAV-4756-2021</api:identifier></api:identifiers></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MRL</api:initials><api:first-names>MRL</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000079527800041&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">182ZJ</api:identifier><api:identifier scheme="pubmed">10197639</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER RESEARCH</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record><api:record format="native" id="22482" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000079527800041" last-modified-when="2014-07-25T11:01:20.79+01:00"><api:citation-count>224</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Prise</api:last-name><api:initials>VE</api:initials><api:first-names>VE</api:first-names><api:separate-first-names><api:first-name>V</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wilson</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Locke</api:last-name><api:initials>RJ</api:initials><api:first-names>RJ</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vojnovic</api:last-name><api:initials>B</api:initials><api:first-names>B</api:first-names><api:separate-first-names><api:first-name>B</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Stratford</api:last-name><api:initials>MRL</api:initials><api:first-names>MRL</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>R</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Dennis</api:last-name><api:initials>MF</api:initials><api:first-names>MF</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-5472</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>7</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER RES</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>FLAVONE ACETIC-ACID</api:keyword><api:keyword>NITRIC-OXIDE</api:keyword><api:keyword>BLOOD-FLOW</api:keyword><api:keyword>SOLID TUMORS</api:keyword><api:keyword>THERAPY</api:keyword><api:keyword>MICE</api:keyword><api:keyword>REDUCTION</api:keyword><api:keyword>INHIBITOR</api:keyword><api:keyword>TUBULIN</api:keyword><api:keyword>VESSELS</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1626</api:begin-page><api:end-page>1634</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>59</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Blood Pressure</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Phosphorylation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Regional Blood Flow</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Stilbenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Vascular Resistance</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Stilbenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Phosphorylation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Blood Pressure</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Vascular Resistance</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Regional Blood Flow</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cardiovascular</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cardiovascular</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Blood Pressure</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">NG-Nitroarginine Methyl Ester</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Phosphorylation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Rats</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Regional Blood Flow</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Stilbenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Vascular Resistance</api:keyword><api:keyword origin="record-data" source="wos">FLAVONE ACETIC-ACID</api:keyword><api:keyword origin="record-data" source="wos">NITRIC-OXIDE</api:keyword><api:keyword origin="record-data" source="wos">BLOOD-FLOW</api:keyword><api:keyword origin="record-data" source="wos">SOLID TUMORS</api:keyword><api:keyword origin="record-data" source="wos">THERAPY</api:keyword><api:keyword origin="record-data" source="wos">MICE</api:keyword><api:keyword origin="record-data" source="wos">REDUCTION</api:keyword><api:keyword origin="record-data" source="wos">INHIBITOR</api:keyword><api:keyword origin="record-data" source="wos">TUBULIN</api:keyword><api:keyword origin="record-data" source="wos">VESSELS</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3101 Biochemistry and cell biology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0008-5472" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973697" title="Cancer Research"><api:records><api:record source-name="summary"><api:title>Cancer Research</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/179/relationships"/></api:object></api:result></api:response>